Bard Geesaman
Partner @ F2 Ventures
Cambridge, United States
Bard Geesaman is a Series B investor at F2 Ventures in Cambridge focused on Biopharma and Therapeutics. Bard Geesaman is the Managing Director at MPM Capital.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Bard Geesaman invests in
Stages Bard Geesaman invests in
Countries Bard Geesaman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 1 (20%)
- Therapeutics 1 (20%)
- Biotechnology 1 (20%)
Stage
- Series B 1 (20%)
- Series C 1 (20%)
- Series D 1 (20%)
- Series E 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $70M / Series E / Feb 27, 2015 | ||
| Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $38.5M / Series D / Jul 23, 2012 | ||
| Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $44M / Series C / Nov 15, 2006 | ||
| Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. Itis applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed. | $7.7M / Series B / Sep 12, 2005 | ||
| See all 5 investments → | |||
Co-Investors
About F2 Ventures
F2 Ventures is a healthcare investment platform focused on arbitrage opportunities across the biotech sector, targeting innovation at the right stage for maximum impact.
F2 Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Morana Jovan-Embiricos
Managing Partner & Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bard Geesaman invest in?
Bard Geesaman invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bard Geesaman?
Public channels for Bard Geesaman include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bard Geesaman last invest?
The most recent investment recorded for Bard Geesaman closed in Feb 2015. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
